Your browser doesn't support javascript.
loading
Primary Tumor Resection Is Associated with Improved Survival in Stage IV Colorectal Cancer: An Instrumental Variable Analysis.
Xu, Hong; Xia, Zuguang; Jia, Xiaoyan; Chen, Kai; Li, Dapeng; Dai, Yun; Tao, Min; Mao, Yixiang.
Afiliação
  • Xu H; Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Xia Z; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Jia X; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Chen K; Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Li D; Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Dai Y; Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Tao M; Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Mao Y; Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Sci Rep ; 5: 16516, 2015 Nov 13.
Article em En | MEDLINE | ID: mdl-26563729
Primary tumor resection (PTR) is recommended for patients with unresectable stage IV colorectal cancer (CRC) who present with symptoms related to their primary tumor. However, the survival benefit of PTR for asymptomatic patients is controversial. We investigated the change in PTR rates and the contribution of PTR to survival in patients with unresectable stage IV CRC over the past two decades in the United States. Clinicopathological factors and long-term survival were compared for 44 514 patients diagnosed with unresectable stage IV CRC from January 1, 1988, through December 31, 2010, who had or had not undergone PTR. Multivariable Cox regression and the instrumental variable method were used to identify independent factors for survival. Of the 44 514 patients with unresectable stage IV CRC, 27 931 (62.7%) had undergone PTR. The annual rate of PTR decreased from 74.4% to 50.2% diagnosed in 1988 and 2010, and the median overall survival increased for both PTR and non-PTR patients. Instrumental variable analyses revealed that PTR was associated with better overall, cancer-specific, and other-cause survival of patients with unresectable stage IV CRC.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Programa de SEER Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Programa de SEER Idioma: En Ano de publicação: 2015 Tipo de documento: Article